Finance

Novo Nordisk to cut US list prices of Ozempic, Wegovy as of 2027

Published by Global Banking & Finance Review

Posted on February 24, 2026

1 min read

· Last updated: April 2, 2026

Add as preferred source on Google
Novo Nordisk to cut US list prices of Ozempic, Wegovy as of 2027
Global Banking & Finance Awards 2026 — Call for Entries

COPENHAGEN, Feb 24 (Reuters) - Danish drugmaker Novo Nordisk said on Tuesday it plans to slash the U.S. list prices of its blockbuster weight-loss drug Wegovy and diabetes drug Ozempic by up to 50%

Novo Nordisk to Slash U.S. List Prices for Ozempic and Wegovy in 2027

U.S. List-Price Cuts Announced for 2027

COPENHAGEN, Feb 24 (Reuters) - Danish drugmaker Novo Nordisk said on Tuesday it plans to slash the U.S. list prices of its blockbuster weight-loss drug Wegovy and diabetes drug Ozempic by up to 50% and 35% respectively as of January next year.

Drugs Affected: Ozempic and Wegovy

(Reporting by Louise Rasmussen, editing by Terje Solsvik)

Key Takeaways

  • Novo Nordisk will reduce U.S. list prices for Wegovy by ~50% and Ozempic by ~35% from Jan 1, 2027, with a new $675 monthly price point. (prnewswire.com)
  • The changes apply to list prices (WAC) and do not alter existing direct-to-patient self‑pay programs. (prnewswire.com)
  • Rybelsus (oral semaglutide) is also included in the reset to $675 per month. (prnewswire.com)
  • Move targets affordability for patients with high‑deductible or coinsurance plans and may impact payer negotiations. (prnewswire.com)
  • The cuts come amid intense GLP‑1 competition, notably from Eli Lilly’s offerings. (axios.com)

References

Frequently Asked Questions

What is the main topic?
Novo Nordisk plans to cut U.S. list prices for its semaglutide drugs Wegovy and Ozempic from January 1, 2027, with Wegovy down about 50% and Ozempic about 35%, to $675 per month. ([prnewswire.com](https://www.prnewswire.com/news-releases/novo-nordisk-announces-significant-reduction-in-us-list-price-for-wegovy-ozempic-and-rybelsus-semaglutide-medicines-building-on-continued-efforts-to-expand-access-302695705.html?utm_source=openai))
When do the price cuts take effect and which drugs are covered?
The new list prices start January 1, 2027, and cover Wegovy, Ozempic, and Rybelsus in the U.S. market. ([prnewswire.com](https://www.prnewswire.com/news-releases/novo-nordisk-announces-significant-reduction-in-us-list-price-for-wegovy-ozempic-and-rybelsus-semaglutide-medicines-building-on-continued-efforts-to-expand-access-302695705.html?utm_source=openai))
Will this lower out-of-pocket costs for all patients?
It’s designed to help patients whose costs are tied to list prices, such as those with high deductibles or coinsurance. Existing direct self‑pay programs are unchanged. ([prnewswire.com](https://www.prnewswire.com/news-releases/novo-nordisk-announces-significant-reduction-in-us-list-price-for-wegovy-ozempic-and-rybelsus-semaglutide-medicines-building-on-continued-efforts-to-expand-access-302695705.html?utm_source=openai))

Tags

Related Articles

More from Finance

Explore more articles in the Finance category